Regeneron Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Regeneron Pharmaceuticals Inc. (REGN)

Q4 2011 Earnings Call

February 13, 2012 8:30 am ET

Executives

Dr. Leonard Schleifer – President, Chief Executive Officer

Murray Goldberg – Chief Financial Officer

Robert Terifay – Senior Vice President, Commercial

Dr. Michael Aberman – Vice President, Strategy and Investor Relations

Analysts

Jim Birchenough – BMO Capital

Jason Kantor – RBC Capital Markets

Josh Schimmer – Leerink Swann

Alethia Young – Deutsche Bank

Chris Raymond – Robert W. Baird

Steve Byrne – Bank of America

Biren Amin – Jefferies

Mani Mohindru – ThinkEquity

Yaron Werber - Citigroup

Geoff Meacham – JP Morgan

Phil Nadeau – Cowen & Company

Presentation

Operator

Good morning ladies and gentlemen. Welcome to the Regeneron Pharmaceuticals Conference Call to discuss the fourth quarter and full-year 2011 financial results. My name is Latoya and I’ll be your coordinator for today. At this time, all participants are in a listen-only mode. We will conduct a question and answer session towards the end of the call. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Dr. Aberman, Vice President of Strategy and Investor Relations for Regeneron. Please proceed, Dr. Aberman.

Dr. Michael Aberman

Thank you very much. Good morning and welcome to Regeneron Pharmaceuticals’ Fourth Quarter and Full-Year 2011 conference call. An archive of this webcast will be available on our website under Events and Presentations for 30 days.

Joining me on the call today is Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; Murray Goldberg, Chief Financial Officer; and Robert Terifay, Senior Vice President, Commercial. After our prepared remarks, we will open the call for questions and answers.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round